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Objective: The possibility of using Ring PTFE graft as venous bypass to preserve arteriovenous graft function and reduce 
upper extremity swelling. 
Methods: Twenty-two patients with stenosis/occlusion f the brachial-axillary-subclavian vein segment in haemodialysis 
patients (n = I9) and patients with penetration i jury (n = 3) who were not candidates for balloon angioplasty were treated 
with ring PTFE venous bypass in renal patients and jugular to axillary vein transposition for trauma patients and followed 
for 10-87 months (mean 31) using venography, Doppler analysis and Duplex scanning. 
Results: There was no death or neurologic deficit resulting from the venous bypass. Resolution of swelling occurred in 8-48 
h. 19/22 (86%) of the bypasses and 3/3 transpositions remained patent after a mean follow-up of 31 months (10-87) 
months. The attrition was due to AV graft occlusion (n = 2) and infection requiring graft removal (n = 1). 
Conclusions: Ring PTFE graft is an acceptable v nous bypass for brachial-axillary-subclavian stenosis/occlusion to reduce 
arm swelling and preserve the function of AV grafts in patients with lesions not amendable with balloon angioplasty or 
thrombolytic therapy. Jugular-axillary transposition is inappropriate for renal patients. 
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Introduction 
Since the introduction of percutaneous dialysis cathe- 
ter placement in the subclavian or internal jugular 
vein for temporary dialysis, the incidence of innomi- 
nate, subclavian, axillary or brachial vein stenosis or 
occlusion has increased significantly. 1-5 Although the 
aetiology responsible for these complications i  not 
well defined, the sequelae of venous hypertension, 
swelling, cutaneous exudation and threatened throm- 
bosis of the arteriovenous graft (AVG) in the upper 
extremity are well recognised. This communication 
discusses (1) the extra-anatomic venous bypass to 
alleviate venous hypertension (2) method of arter- 
iovenous graft preservation (3) selection of the bypass 
conduit. 
Materials and Methods 
Twenty-two patients (13 male, 9 female) with the 
mean age of 58 years (42-71) underwent extra- 
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Table 1. Distribution of venous  obstruction 
Brachiosubclavian vein thrombosis 
Axillosubclavian vein thrombosis 
Subclavian vein thrombosis 
Brachiocephalic vein thrombosis 
Brachiosubclavian-int. jugular vein stenosis 
Subclavian-int. jugular vein stenosis 
anatomic bypasses for treatment of upper extremity 
massive swelling (n--22), skin exudation (n = 8), blis- 
ter formation (n = 4), and breast enlargement (n = 7) 
due to occlusion of brachiosubclavian vein (n = 5), 
axillosubclavian vein (n = 8), subclavian vein (n--2), 
brachiocephalic vein (n = 1), stenosis of brachiosub- 
clavian-internal jugular veins (n = 3), and subclavian- 
internal jugular veins (n = 3) (Table 1). Except for the 
three internal jugular vein to axillary vein transposi- 
tion performed in patients with penetration i jury, 19 
of the 22 limbs belong to chronic renal failure patients 
who were dependent on the AVGs for haemodialysis 
(Table 2). In 13/19 (63%) the patients had no addi- 
tional available sites in the upper extremity for 
additional AVG. In 3/19 (16%) the patients have had 
only one site in both upper extremities available for 
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Table 2. Distribution of patients 
Trauma related subclavian d axilla vein thrombosis 
Dialysis catheter induced axillary-subclavian-jugular 
vein thrombosis 
3 (13.6%) 
19 (86.4%) 
AVG and 3/19 (16%) patients had one site remaining 
in each upper extremity. 
All patients were screened for chronic oagulopathy 
(antithrombin III, protein C and S, fibrinogen, plasmi- 
nogen). Antithrombin III deficiency was found in 4/21 
patients (19%). They were treated with long-term low 
dose Coumadin (2.5-5 mg/day). Contrast venog- 
raphy, Duplex scan and Doppler ultrasonography 
were performed before and after the operations. Each 
AVG was evaluated in the clinic at 3 months interval 
for haematoma, aneurysm, pseudoaneurysm, infec- 
tion and increased venous pressure during dialysis. 
Doppler analysis, Duplex scan and venogram were 
used selectively to supplement physical examination 
whenever potential complications were suspected. 
Surgical techniques 
Brachial or axillary vein to internal jugular vein 
bypass using 8-10mm ring Gore-Tex PTFE graft was 
the standard procedure. Internal jugular veins were 
dissected free between the bifurcated attachment of 
the sternocleidomastoid muscle to the clavicle (Fig. 
1A). Following the end-to-side anastomosis to the 
internal jugular vein, the PTFE graft was placed in a 
retroclavicular tunnel and the axillary or brachial 
anastomosis was constructed also in an end-to-side 
configuration (Fig. 1B). 
The internal jugular to axillary vein transposition 
was accomplished by mobilising the internal jugular 
vein for adequate length through an oblique incision 
placed along the anterior border of the sternocleido- 
mastoid muscle. The axillary vein was exposed 
through a supraclavicular incision placed along the 
clavicle. Transection of the internal jugular vein at the 
level of the mandible provided adequate length for 
transposition to the axillary vein. 
Postoperative enography was performed routinely 
prior to patients' discharge from the hospital (Figs. 2 
and 3). Elastic bandage wrapping for 24 48 h follow- 
ing the bypass has significantly reduced arm swelling. 
One dose of intravenous prophylatic antibotic was 
given preoperatively to minimise potential wound 
infection. 
Results 
There was no death or neurologic deficit resulting 
from the venous bypass procedures. Transient vocal 
cord dysfunction attributed to traumatic intubation 
was noted in one patient following jugular-jugular 
bypass. 
Resolution of the upper extremity swelling gen- 
erally occurred in a 8-48 h. Jobst compression sleeve to 
control swelling for 3-7 weeks was needed in two 
patients with brachial to contralateral internal jugular 
bypass and in axillary-jugular bypass. 
A total of 19/22 (86.3%) bypass grafts remained 
patent without arm swelling after a 10-87 month 
(a) 
(b) 
Fig. 1. (A) Intraoperative photograph of ring PTFE graft (G) in an 
end-to-side anastomosis to the contralateral internal jugular vein 
(IJ). (B) Intraoperative photograph of ring PTFE graft (G) in an end- 
to-side anastomosis to the contralateral axillary vein (AV) for 
innominate vein occlusion. The graft was placed subcutaneously 
across the neck (N). 
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(mean 31) follow-up (Table 3). Two jugular vein 
stenoses after brachiointernal jugular bypass were 
successfully revised using vein patch angioplasty at 
the jugular anastomosis. The jugular-jugular bypass 
for brachiocephalic vein occlusion was functional for 
17 months until the AVG was thrombosed (Fig. 3). 
A total of 3/22 (13.7%) jugular to axillary transposi- 
tion had no postoperative adverse consequence. There 
was no cervical venous congestion or swelling. How- 
ever resolution of arm swelling was evident. 
Arterial-venous graft occlusion (2/22) and AVG 
infection (1/22) have accounted for the sole attrition of 
venous bypass failure in our study. 
Fig. 2. Post brachiojugular bypass venogram. Arrows indicate the 
course o5 the brachiojugular bypass. Internal jugular (IJ). 
Fig. 3. Internal jugular to internal jugular bypass with ring PTFE 
graft. Open arrows indicate sites of anastomoses. 
Discussion 
Although arteriovenous fistula is preferred to pros- 
thetic or biologic arteriovenous access, AVG is con- 
sidered an acceptable substitute for patients who 
urgently need a vascular access for haemodialysis. The 
abuse of the convenience of jugular or subclavian 
catheter for temporary dialysis has contributed to the 
high incidence of stenosis plus occlusion of axillary, 
subclavian and jugular veins. 1-s This complication ot 
only affects the function of the upper extremity but 
also threatens the patency of the AVG. The incidence 
of subclavian-axillary vein stenosis/occlusion has 
initially surpassed the similar complication encoun- 
tered in jugular veins due to the preference of placing 
the dialysis catheter in the subclavian vein. However, 
the incidence of jugular vein stenosis/occlusion is 
becoming more common with the increased frequency 
of internal jugular vein catheter placement. 6 
There were several theories regarding the sub- 
clavian, axillar~ and jugular vein stenosis/occlu- 
sion. 6-9 Fibrotic reaction from repeated percutaneous 
cannulation, delayed catheter emoval extrinsic hae- 
matoma compression, and reactive fibroplasia secon- 
dary to intraluminal catheter vibration generated by 
the cyclic cardiac contraction are among the proposed 
aetiologic factors. 6'1° Coagulopathy is a potential 
complication for graft thrombosis. However, it is 
uncommon in our series despite the high incidence of 
antithrombin III deficiency identified in 4/21 (19%) in 
our patients. Low-dose Coumadin (2.5-5.0 mg) daily 
has been found beneficial in selected patients without 
significantly altering the prothrombin time (12-15 s). 
Elevated sedimentation rates in lupus erythematosis 
are also known to cause AVG thrombosis and has 
accounted for one patient in our series. Whether 
improvement ofhaematocrit from erythropoetin treat- 
ment, per se, has any effects on blood coagulability in 
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Table 3. Demographic data of upper extremity venous bypass 
Procedures No. Sex Age Occlusion Follow-up AVG Swelling Complication 
Brachioqugular 15 8M7F 48-71 Brach-subcl. 5 10-49 mon Functional (--) 1 graft infect, and 
Ax-Subcl. 8 ocd. 
Subclavian 2 I graft occl. 
after AV graft 
thrombosed 
Jugular-jugular 1 M 51 Brach-cephalic 17 mon Functional (--) 
Brach-contra. Jugular 3 2M 1F 56-71 Brach-subclav. 16-18 mon Functional (--) i bypass occlus. 
int. Jugular after AV graft 
thrombosed 
Jugular-axillary 3 2M 1F 42-68 axillo-subcl. 42,-87 mon N/A  (--) none, bypass patent. 
renal patients is not known and is worthy of further 
investigation. 1°-13 
Bypassing the occluded segment of the brachiosub- 
clavian or innominate vein using ring Gore-Tex PTFE 
graft in this study has produced surprisingly good 
and durable results in preserving AV graft patency, 
reducing arm swelling, breast swelling, cutaneous 
exudation, pain and restoring function to the 
limb. 14-16 Also, no obvious adverse sequelae resulted 
from these venous bypass procedures. On the basis of 
this promising and encouraging data, the traditional 
approach of AVG ligation to reduce swelling is no 
longer necessary and should be avoided particularly 
in patients who have limited sites available for future 
AVG. 3,17 
Balloon dilation 5'1s and thrombolytic therapy 1°'18-2° 
have been reported with acceptable results but has 
high incidence of recurrence. 21-22 Five renal patients 
presented in these studies were candidates whose 
axillosubclavian vein (n = 3) and subclavian veins 
(n = 2) could not be resolved with thrombolytic ther- 
apy. The remaining 14/19 renal patients were not 
amendable for balloon angioplasty due to the long 
segment of venous occlusion. 
It is well aware that longer follow-up is needed to 
more accurately define the durability and the true 
value of venous bypass in the preservation of the 
function of the upper extremity and the AVG. None- 
theless, the patency rate of 16/19 (84%) in a follow-up 
of 10-87 months (mean 31) has produced encouraging 
and creditable result in ring PTFE graft bypass for 
venous outflow obstruction of the upper extremity 
and AVG preservation. The high incidence of ring 
PTFE venous bypass graft patency in this study can in 
part be attributed to (1) ring PTFE graft is resistant to 
compression and kink, (2) the distal AVG functioning 
as a fistula enhances venous flow and improves 
patency. 
Balloon dilation in conjunction with 76.5% stenting 
of axillary-subclavian stenosis/occlusion did not yield 
promising results even in short erm follow-up of 9-13 
months by Criado et al. 21 These findings are in 
agreement with our experience and histologic findings 
that fibroplasia in venous stenosis is resistant o 
dilation and stenting. 22 
The pertinent information that emerged from this 
study are: (1) the success rate of ring PTFE graft, and 
(2) spiral saphenous vein or femoral vein for venous 
bypass are no longer necessary. The elegant approach 
of jugular to axillary vein transposition is more suited 
for non-renal patients. In renal patients the jugular 
vein should be preserved as potential site for future 
temporary or permanent catheter access. A pro- 
spective randomised study comparing the patency 
and durability of autogenous versus ring PTFE graft 
will be the most ideal and more scientific study. 
However, the fact remains that ring PTFE access with 
a distal AVG has been proven effective in reducing 
arm swelling and AVG preservation. 
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